Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50749 |
Name | peripheral T-cell lymphoma |
Definition | A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 wild-type | ALRN-6924 | peripheral T-cell lymphoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01431209 | Phase II | Ruxolitinib | Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01644253 | Phase I | Idelalisib + Otlertuzumab + Rituximab Otlertuzumab + Rituximab Obinutuzumab + Otlertuzumab Ibrutinib + Otlertuzumab Bendamustine + Otlertuzumab | Phase 1b Safety and Efficacy Study of TRU-016 | Terminated | USA | 0 |
NCT02181218 | Phase I | Pegfilgrastim Romidepsin Dexamethasone + Gemcitabine + Oxaliplatin | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | Completed | USA | 0 |
NCT02232516 | Phase II | Lenalidomide + Romidepsin | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02273739 | Phase Ib/II | Enasidenib | Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | Completed | USA | FRA | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | ARG | 0 |
NCT02464228 | Phase II | Tipifarnib | Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma | Completed | USA | ESP | 1 |
NCT02495415 | Phase II | Fenretinide | Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas | Unknown status | USA | 0 |
NCT02512497 | Phase I | Romidepsin Busulfan + Fludarabine + Romidepsin | Romidepsin Maintenance After Allogeneic Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02520791 | Phase I | MEDI-570 | Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma | Active, not recruiting | USA | CAN | 0 |
NCT02535247 | Phase II | Pembrolizumab | Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma | Terminated | USA | 0 |
NCT02567656 | Phase I | Tenalisib | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma | Completed | USA | 0 |
NCT02576496 | Phase I | Tinostamustine | Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | Completed | USA | NLD | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02581631 | Phase Ib/II | Brentuximab vedotin + Nivolumab | A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) | Completed | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT02689453 | Phase I | Alemtuzumab + rhIL-15 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | Completed | USA | 0 |
NCT02797470 | Phase Ib/II | Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT02875002 | Phase I | Belinostat + Volasertib | Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas | Withdrawn | USA | 0 |
NCT02978625 | Phase II | Nivolumab + Talimogene laherparepvec | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Active, not recruiting | USA | 0 |
NCT03011814 | Phase Ib/II | Durvalumab Durvalumab + Lenalidomide | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03049449 | Phase I | Cyclophosphamide + Fludarabine 5F11-28Z CAR-T cells | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |
NCT03075553 | Phase II | Nivolumab | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Terminated | USA | 0 |
NCT03081910 | Phase I | CD5 CAR-T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03161223 | Phase Ib/II | Durvalumab + Romidepsin Azacitidine + Durvalumab Azacitidine + Durvalumab + Romidepsin Durvalumab + Pralatrexate + Romidepsin | Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | Unknown status | USA | 0 |
NCT03217643 | Phase II | Brentuximab vedotin | CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. (EATL-001) | Completed | FRA | 0 |
NCT03218683 | Phase I | AZD5991 | Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. | Terminated | USA | 0 |
NCT03240211 | Phase I | Pembrolizumab + Pralatrexate Decitabine + Pembrolizumab + Pralatrexate Decitabine + Pembrolizumab | Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | Recruiting | USA | 0 |
NCT03264131 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | Active, not recruiting | USA | 0 |
NCT03278782 | Phase Ib/II | Romidepsin Pembrolizumab + Romidepsin | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | Active, not recruiting | USA | 0 |
NCT03328104 | Phase I | Cyclophosphamide + Etoposide + Everolimus + Nelarabine | Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma (ENCERT) | Completed | USA | 0 |
NCT03372057 | Phase II | Duvelisib | A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) | Completed | USA | ITA | GBR | DEU | 0 |
NCT03409432 | Phase II | Brentuximab vedotin + Lenalidomide | Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03534180 | Phase II | Venetoclax | Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma | Completed | USA | 0 |
NCT03547700 | Phase Ib/II | Ixazomib + Romidepsin | Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | Active, not recruiting | USA | 0 |
NCT03586999 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Sulfate | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | Completed | USA | 0 |
NCT03590574 | Phase Ib/II | AUTO4 | Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma | Active, not recruiting | GBR | ESP | 0 |
NCT03598998 | Phase Ib/II | Pembrolizumab + Pralatrexate | Pembrolizumab and Pralatrexate in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphomas | Active, not recruiting | USA | 0 |
NCT03601819 | Phase I | Pacritinib | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Terminated | USA | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03719105 | Phase I | Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | Recruiting | USA | 0 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |
NCT03900442 | Phase I | GGTI-2418 | Phase 1 Study of PTX-100 in Patients With Advanced Malignancies | Unknown status | AUS | 0 |
NCT03902184 | Phase II | Gemcitabine + Lacutamab + Oxaliplatin Lacutamab | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) | Active, not recruiting | USA | POL | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT03905135 | Phase I | Avelumab + rhIL-15 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | Completed | USA | 0 |
NCT03921879 | Phase I | OT-82 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | Unknown status | USA | 0 |
NCT03927105 | Phase II | Cabiralizumab + Nivolumab | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma | Completed | USA | 0 |
NCT03947255 | Phase II | Brentuximab vedotin | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma | Terminated | USA | 0 |
NCT04018248 | Phase I | BR101801 | BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | Active, not recruiting | USA | 1 |
NCT04072458 | Phase I | BP1002 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Recruiting | USA | 0 |
NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT04083495 | Phase II | ATLCAR.CD30 cells | CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma | Recruiting | USA | 0 |
NCT04101331 | Phase II | AFM13 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT) | Completed | USA | TUR | POL | ITA | FRA | ESP | DEU | AUS | 2 |
NCT04105010 | Phase II | Golidocitinib | Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) | Completed | USA | AUS | 2 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Completed | USA | 0 |
NCT04217317 | Phase II | Bendamustine + CPI-613 | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04234048 | Phase I | Fenretinide | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04334174 | Phase II | Brentuximab vedotin | Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T) | Withdrawn | USA | 0 |
NCT04464798 | Phase I | Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Active, not recruiting | USA | ITA | FRA | DEU | 2 |
NCT04569032 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CZE | 0 |
NCT04639843 | Phase I | Azacitidine + Doxorubicin + Duvelisib + Romidepsin | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | Withdrawn | USA | 0 |
NCT04653649 | Phase Ib/II | HSP-CAR30 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | Unknown status | ESP | 0 |
NCT04703192 | Phase II | DS-3201b | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT04747236 | Phase II | Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin | A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) | Recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04774068 | Phase I | Romidepsin Parsaclisib + Romidepsin | Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | Active, not recruiting | USA | 0 |
NCT04795869 | Phase II | Brentuximab vedotin + Pembrolizumab | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | Withdrawn | USA | 0 |
NCT04803201 | Phase II | Cyclophosphamide + Doxorubicin + Duvelisib + Etoposide + Prednisone + Vincristine Sulfate Azacitidine + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | Recruiting | USA | 0 |
NCT04858256 | Phase II | Pacritinib | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | Recruiting | USA | 0 |
NCT04984837 | Phase II | Gemcitabine + Oxaliplatin Gemcitabine + Lacutamab + Oxaliplatin | Study of Lacutamab in Peripheral T-cell Lymphoma | Recruiting | FRA | ESP | DEU | BEL | 0 |
NCT05006664 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | Unknown status | CZE | 0 |
NCT05010005 | Phase I | Duvelisib + Ruxolitinib | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | Active, not recruiting | USA | 0 |
NCT05011058 | Phase II | CHR-3996 CHR-3996 + Valganciclovir | An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 5 |
NCT05079282 | Phase I | ONO-4685 | Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Recruiting | USA | 0 |
NCT05138458 | Phase Ib/II | Cyclophosphamide + Fludarabine + MT-101 MT-101 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (IMAGINE) | Suspended | USA | 0 |
NCT05140382 | Phase II | AZD4573 | AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL | Completed | USA | SWE | ITA | GBR | FRA | AUS | 2 |
NCT05239910 | Phase II | Cyclophosphamide + Doxorubicin + Prednisone + Tenalisib + Vincristine Sulfate | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL | Withdrawn | USA | 0 |
NCT05274997 | Phase II | Linperlisib | A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | Unknown status | USA | 0 |
NCT05321147 | Phase I | Lacutamab | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | Completed | USA | 1 |
NCT05346809 | Phase II | Isatuximab | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | Recruiting | USA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05371054 | Phase Ib/II | Prednisone + Venetoclax + VIP152 | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05377827 | Phase I | WU-CART-007 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT05883449 | Phase II | AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) | Recruiting | USA | 0 |
NCT05967416 | Phase I | SIRPant-M | Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT05983965 | Phase I | Tazemetostat Acalabrutinib + Tazemetostat | Study of Tazemetostat in Lymphoid Malignancies | Recruiting | USA | 0 |
NCT06072131 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Cyclophosphamide + Pralatrexate + Prednisone + Vincristine Sulfate Belinostat + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO) | Recruiting | USA | POL | HUN | 2 |
NCT06120504 | Phase I | SGN-35T | A Safety Study of SGN-35T in Adults With Advanced Cancers | Recruiting | USA | GBR | ESP | DNK | CAN | 0 |
NCT06176690 | Phase I | C7R.CD30.CAR-EBVS T-cells | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | Not yet recruiting | USA | 0 |
NCT06254495 | Phase I | SGN-35C | A Safety Study of SGN-35C in Adults With Advanced Cancers | Recruiting | USA | ITA | DNK | 0 |
NCT06420089 | Phase I | Cyclophosphamide + Fludarabine + Senza5 CART5 Senza5 CART5 | CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) (VIPER101) | Recruiting | USA | 0 |
NCT06492304 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT06508463 | Phase I | Cemiplimab + Ipilimumab + VSV-hIFNbeta-NIS | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | Recruiting | USA | 0 |
NCT06561048 | Phase III | Pralatrexate CPI-818 Belinostat | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Recruiting | USA | 0 |
NCT06630091 | Phase II | Cyclophosphamide + Doxorubicin + Golidocitinib + Prednisone + Vincristine Sulfate | A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study | Not yet recruiting | USA | 0 |